

PCT

BEST AVAILABLE COPY
WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 239/88, 475/02, 471/04, A61K 31/505	A1	(11) International Publication Number: WO 97/10221 (43) International Publication Date: 20 March 1997 (20.03.97)
(21) International Application Number: PCT/US96/00886 (22) International Filing Date: 18 January 1996 (18.01.96) (30) Priority Data: 08/529,404 15 September 1995 (15.09.95) US (71) Applicant: TORREY PINES INSTITUTE FOR MOLECULAR STUDIES [US/US]; 3550 General Atomics Court, San Diego, CA 92121 (US). (72) Inventors: HOUGHTEN, Richard, A.; 4939 Rancho Viejo, Del Mar, CA 92014 (US). OSTRESH, John, M.; 315 La Veta Avenue, Encinitas, CA 92024 (US). (74) Agents: PERKINS, Susan, M. et al.; Campbell & Flores, Suite 700, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).	(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: SYNTHESIS OF QUINAZOLINONE LIBRARIES (57) Abstract The present invention provides synthetic combinatorial libraries of organic compounds based on the quinazolinone ring.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

SYNTHESIS OF QUINAZOLINONE LIBRARIES

BACKGROUND OF THE INVENTIONFIELD OF THE INVENTION

The present invention relates generally to the
5 field of synthetic combinatorial libraries and, more
specifically, to the generation of libraries of small
organic compounds based on the quinazolinone ring.

BACKGROUND INFORMATION

Interest in the medicinal chemistry of
10 quinazoline derivatives was stimulated in the early
1950's with the elucidation of a quinazoline alkaloid, 3-
[β -keto- γ (3-hydroxy-2-piperidyl)-propyl]-4-quinazolinone,
from an Asian plant known for its antimalarial
properties. In a quest to find additional antimalarial
15 agents, various substituted quinazolines have been
synthesized. Of particular import was the synthesis of
the derivative 2-methyl-3-o-tolyl-4-(3H)-quinazolinone.
This compound, known by the name methaqualone, though
ineffective against protozoa, was found to be a potent
20 hypnotic.

Since the introduction of methaqualone and its
discovery as a hypnotic, the pharmacological activity of
quinazolinones, and related compounds, has been
investigated. Quinazolinones and derivatives thereof are
25 now known to have a wide variety of biological

properties, including hypnotic, sedative, analgesic, anticonvulsant, antitussive and anti-inflammatory effects.

The classical organic synthesis of variously substituted quinazolinones is known. For example, as described in Ager et al., J. of Med. Chem., 20:379-386 (1977), quinazolinones can be obtained by acid-catalyzed condensation of N-acylanthranilic acids with aromatic primary amines. However, the current synthesis and study of quinazolinones is a slow process. Each quinazolinone must be individually synthesized and separately tested. There exists a need to more efficiently synthesize and test various quinazolinones.


During the past four years there has been substantial development of chemically synthesized combinatorial libraries (SCLs) made up of peptides. The preparation and use of synthetic peptide combinatorial libraries has been described, for example, in Houghten et al., Nature 354, 84 (1991). Such SCLs provide the efficient synthesis of an extraordinary number of various peptides and screening of the library rapidly identifies lead pharmaceutical compounds. Combinatorial approaches have recently been extended to "organic," or non-peptidic libraries, as described, for example, in Gordon et al., J. Med. Chem., 37:1385-1401 (1994). The organic libraries to present date, however, are of limited diversity and generally relate to peptidomimetic compounds; in other words, organic molecules that retain peptide chain pharmacophore groups similar to those

present in the corresponding peptide. There exists a need to develop more complex "organic" libraries based on heterocyclic medicinal compounds which would require less optimization, synthesis, modification, and testing to
5 bring an organic pharmaceutical product to fruition. In particular, such organic libraries are needed to prepare and screen quinazolinones and derivatives thereof. This invention satisfies these needs and provides related advantages as well.

10

SUMMARY OF THE INVENTION


The present invention relates to the generation of synthetic combinatorial libraries of organic compounds based on the quinazolinone ring of the formula:



wherein R¹, R², R³, and Y have the meanings provided
15 below.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a library of five or more variously substituted quinazolinones wherein each quinazolinone contained within the mixture has the
 5 basic ring structure of Formula I:






In the above Formula I:

R¹ is a hydrogen atom, C₁ to C₆ alkyl; C₁ to C₆ substituted alkyl, C₇ to C₁₂ phenylalkyl, C₇ to C₁₂ substituted phenylalkyl, phenyl, substituted phenyl, C₃ to C₇,
 10 cycloalkyl, or C₃ to C₇ substituted cycloalkyl;

R² is a hydrogen atom, halo, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₂ to C₇ alkenyl, C₂ to C₇ alkynyl, C₁ to C₆ substituted alkyl, C₂ to C₇,
 15 substituted alkenyl, C₂ to C₇ substituted alkynyl, C₁ to C₄ alkoxy, C₁ to C₇ acyloxy, C₁ to C₇ acyl, C₃ to C₇

- cycloalkyl, C₃ to C₇ substituted cycloalkyl, C₃ to C₇ cycloalkenyl, C₃ to C₇ substituted cycloalkenyl, a heterocyclic ring, C₃ to C₁₂ phenylalkyl, C₇ to C₁₂ substituted phenylalkyl, phenyl, substituted phenyl,
- 5 cyclic C₂ to C₁₀ alkylene, substituted cyclic C₂ to C₁₀ alkylene, cyclic C₂ to C₁₀ heteroalkylene, substituted cyclic C₂ to C₁₀ heteroalkylene, carboxy, protected carboxy, hydroxymethyl, protected hydroxymethyl, (monosubstituted)amino, protected
- 10 (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, C₁ to C₄ alkylthio, C₁ to C₄ alkylsulfonyl, methylsulfonylamino, C₁ to C₄ alkylsulfoxide, phenylthio, substituted phenylthio, phenylsulfoxide, substituted phenylsulfoxide,
- 15 phenylsulfonyl, or substituted phenylsulfonyl;
- R³ is C₁ to C₆ alkyl, C₂ to C₇ alkenyl, C₂ to C₇ alkynyl, C₁ to C₆ substituted alkyl, C₂ to C₇ substituted alkenyl, C₂ to C₇ substituted alkynyl, C₃ to C₇ cycloalkyl, C₃ to C₇ substituted cycloalkyl, C₇ to C₁₂ phenylalkyl, C₇ to C₁₂ substituted phenylalkyl, phenyl, or substituted phenyl; and
- 20 Y may be absent and, if present, is carboxylic acid, carboxamide, protected carboxamide, an amino resin, or a hydroxy resin.

In a preferred embodiment of the above
quinazolinone library, R¹ is n-prop-1,3-yl, n-prop-1,1-yl,
n-pent-1,5-yl, n-hex-1,6-yl, p-benzyl, 2-chloro-*p*-phenyl,
p-phenyl, 2-methyl-*m*-phenyl, 2-hydroxy-*p*-phenyl, and 2-
5 (phenyl)-n-prop-1,3-yl, or the α -carbon and side chain of
an amino acid and more preferably the α -carbon and side
chain of an amino acid as provided in Table I.


TABLE I	
Amino Acid	R ¹
Glycine	- CH ₂ -
Alanine	- CH (CH ₃) -
5 Valine	- CH(CH(CH ₃) ₂) -
Leucine	- CH(CH ₂ CH(CH ₃) ₂) -
Isoleucine	- CH(CH(CH ₃)CH ₂ CH ₃) -
Arginine	- CH(CH ₂ CH ₂ CH ₂ NHCNHNH ₂) -
Serine	- CH(CH ₂ OH) -
10 Threonine	- CH(CH(OH)CH ₃) -
Phenylalanine	- CH (CH ₂ ) -
Tyrosine	- CH (CH ₂  -OH) -
β-Alanine	- CH ₂ - CH ₂ -
Norvaline	- CH(CH ₂ CH ₂ CH ₃) -
15 Norleucine	- (CH(CH ₂ CH ₂ CH ₂ CH ₃) -
Naphthylalanine	- CH (CH ₂ ) -

Also in the preferred embodiment of the above quinazolinone library of Formula I, R² is a hydrogen atom, 6,8-dimethyl, 6-hydroxy, a 1,4-butadienyl moiety such

that a naphthyl ring results, or halo, and more preferably 6,7-difluoro, 6,8-dichloro, or 6,8-dibromo; R³ is methyl; and Y may be present or absent and, if present, is selected from the group consisting of
5 carboxylic acid, carboxamide, protected carboxamide, an amino resin, and a hydroxy resin.

The present invention also provides libraries of various quinazolinone derivatives. Once the initial quinazolinone structure of Formula I is prepared by any
10 one of the above described methods the quinazolinone mixture can be further chemically transformed to extend the range and chemical diversity of the compounds. Using the "libraries from libraries" concept, as described in Ostresh et al., Proc. Natl. Acad. Sci., 91:11138-11142
15 (1994), various libraries of quinazolinone derivatives can be prepared by chemically altering the initial quinazolinone library.

Such quinazolinone derivative libraries can be
20 made by modifying the above described quinazolinone library in a variety of ways. For example, the above quinazolinone library can be modified to yield N-styryl derivatives of quinazolinones. Therefore, the present invention provides a mixture of five or more
25 quinazolinone derivatives of the structure of Formula II:



In the above Formula II, R¹, R², and Y have the same meaning as provided above and R⁴ is as follows:


R⁴ is C₁ to C₆ alkyl; C₁ to C₆ substituted alkyl, C₇ to C₁₂ phenylalkyl, C₇ to C₁₂ substituted phenylalkyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl, or a heterocyclic ring.

In a preferred embodiment of the styryl derivatives of quinazolinone, R¹ is n-prop-1,3-yl, n-prop-1,1-yl, n-pent-1,5-yl, n-hex-1,6-yl, p-benzyl, 2-chloro-p-phenyl, p-phenyl, 2-methyl-m-phenyl, 2-hydroxy-p-phenyl, and 2-(phenyl)-n-prop-1,3-yl, or the α-carbon and side chain of an amino acid and more preferably the α-carbon and side chain of an amino acid as provided in Table I above; R² is a hydrogen atom, 6,8-dimethyl, 6-hydroxy, 1,4-butadienyl moiety such that a naphthyl ring results, or halo, and more preferably 6,7-difluoro, 6,8-dichloro, or 6,8-dibromo; R⁴ is phenyl, 2,4-dichlorophenyl, 2-naphthyl, 2,5-dimethylphenyl, 3,4-difluorophenyl, 4-bromophenyl, 3-(4-methylphenoxy)phenyl, 4-methoxyphenyl, biphenyl, 6-methyl-pyridin-2-yl, 2-

(methoxy)-naphthyl, 2,4,5,-trimethoxyphenyl, or 4-(dimethylamino)phenyl; and


Y may be present or absent and, if present, is carboxylic acid, carboxamide, protected carboxamide, an amino resin,
5 or a hydroxy resin.

Another library containing five or more quinazolinone derivatives provided by the present invention include 1,2-dihydro derivatives having the structure of Formula III:




10 In Formula III, R¹, R², and R³ have the same meanings as provided above.

In yet another embodiment of the present invention, the basic ring nitrogen at position 1 can be alkylated using a variety of alkylating agents to prepare
15 a mixture of five or more quinazolinone derivatives of the following Formula IV:



In Formula IV, R¹, R², R³, and Y are as defined above, and R⁵ is C₁ to C₆ alkyl; C₁ to C₆ substituted alkyl, C₁ to C₄ alkoxy, C₇ to C₁₂ phenylalkyl, C₇ to C₁₂ substituted phenylalkyl, phenyl, or substituted phenyl.

Also provided by the present invention is a library of five or more quinazolinone derivatives having the structure of Formula V:



The substituents R^1 , R^2 , and Y in Formula V are identical to those defined above with respect to Formula

I. The substituent R^6 is as follows:

R^6 is a hydrogen atom, C_1 to C_6 alkyl; C_1 to C_6 substituted
5 alkyl, C_7 to C_{12} phenylalkyl, C_7 to C_{12} substituted
phenylalkyl, phenyl, substituted phenyl, C_3 to C_7
cycloalkyl, C_3 to C_7 substituted cycloalkyl, carboxylic
acid, carboxamide, or protected carboxamide.

In the above Formulae the stereochemistry of
10 the chiral R^1 through R^6 groups can independently be in
the R or S configuration, or a mixture of the two.

In the above Formulae, the term " C_1 to C_6 alkyl"
denotes such radicals as methyl, ethyl, n-propyl,
isopropyl, n-butyl, sec-butyl, tert-butyl, amyl, tert-
15 amyl, hexyl and the like. The preferred " C_1 to C_6 alkyl"
group is methyl.

The term " C_2 to C_7 alkenyl" denotes such
radicals as vinyl, allyl, 2-butenyl, 3-butenyl, 2-
pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl,
20 4-hexenyl, 5-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl,
5-heptenyl, 6-heptenyl, as well as dienes and trienes of
straight and branched chains.

The term " C_2 to C_7 alkynyl" denotes such
radicals as ethynyl, propenyl, butynyl, pentynyl,
25 hexynyl, heptynyl, as well as di- and tri-ynes.

The term "C₁ to C₆ substituted alkyl," "C₂ to C₇ substituted alkenyl," and "C₂ to C₇ substituted alkynyl," denotes that the above C₁ to C₆ alkyl groups and C₂ to C₇ alkenyl and alkynyl groups are substituted by one or
5 more, and preferably one or two, halogen, hydroxy, protected hydroxy, cyclohexyl, naphthyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, imidazolyl, indolyl, pyrrolidinyl, C₁ to C₇ acyloxy,
10 nitro, C₁ to C₄ alkyl ester, carboxy, protected carboxy, carbamoyl, carbamoyloxy, carboxamide, protected carboxamide, cyano, methylsulfonylamino, sulfurhydryl, C₁ to C₄ alkylthio, C₁ to C₄ alkyl sulfonyl or C₁ to C₄ alkoxy groups. The substituted alkyl groups may be substituted
15 once or more, and preferably once or twice, with the same or with different substituents.

Examples of the above substituted alkyl groups include the cyanomethyl, nitromethyl, chloromethyl, hydroxymethyl, tetrahydropyranyloxymethyl,
20 trityloxymethyl, propionyloxymethyl, aminomethyl, carboxymethyl, allyloxycarbonylmethyl, allylcaroxybonylaminomethyl, carbamoyloxymethyl, methoxymethyl, ethoxymethyl, t-butoxymethyl, acetoxymethyl, chloromethyl, bromomethyl, iodomethyl, 6-
25 hydroxyhexyl, 2,4-dichloro(n-butyl), 2-amino(iso-propyl), 2-carbamoyloxyethyl chloroethyl, bromoethyl, fluoroethyl, iodoethyl, chloropropyl, bromopropyl, fluoropropyl, iodopropyl and the like.

The term "C₁ to C₄ alkoxy" as used herein denotes groups such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy and like groups. A preferred C₁ to C₄ alkoxy group is methoxy.

5 The term "C₁ to C₇ acyloxy" denotes herein groups such as formyloxy, acetoxy, propionyloxy, butyryloxy, pentanoyloxy, hexanoyloxy, heptanoyloxy, and the like.

 Similarly, the term "C₁ to C₇ acyl" encompasses
10 groups such as formyl, acetyl, propionyl, butyryl, pentanoyl, hexanoyl, heptanoyl, benzoyl and the like.

 The substituent term "C₃ to C₇ cycloalkyl" includes the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl rings. The substituent term "C₃
15 to C₇ substituted cycloalkyl" indicates the above cycloalkyl rings substituted by a halogen, hydroxy, protected hydroxy, C₁ to C₆ alkyl, C₁ to C₄ alkoxy, carboxy, protected carboxy, amino, or protected amino.

 The substituent term "C₃ to C₇ cycloalkenyl" indicates a 1,2, or 3-cyclopentenyl ring, a 1,2,3 or 4-cyclohexenyl ring or a 1,2,3,4 or 5-cycloheptenyl ring, while the term "substituted C₃ to C₇ cycloalkenyl" denotes the above C₃ to C₇ cycloalkenyl rings substituted by a C₁ to C₆ alkyl radical, halogen, hydroxy, protected hydroxy,
25 C₁ to C₄ alkoxy, carboxy, protected carboxy, amino, or protected amino.

The term "heterocyclic ring" denotes optionally substituted five-membered or six-membered rings that have 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms. These five-membered or six-membered rings may be fully unsaturated or partially unsaturated, with fully unsaturated rings being preferred. Preferred heterocyclic rings include pyridino, pyrimidino, and pyrazino rings.

The term " C_7 to C_{12} phenylalkyl" denotes a C_1 to C_6 alkyl group substituted at any position by a phenyl ring. Examples of such a group include benzyl, 2-phenylethyl, 3-phenyl-(n-prop-1-yl), 4-phenyl-(-hex-1-yl), 3-phenyl-(n-am-2-yl), 3-phenyl-(sec-butyl), and the like. A preferred group is the benzyl group.

The term " C_7 to C_{12} substituted phenylalkyl" denotes a C_7 to C_{12} arylalkyl group substituted on the C_1 to C_6 alkyl portion with one or more, and preferably one or two, groups chosen from halogen, hydroxy, protected hydroxy, keto, C_2 to C_3 cyclic ketal, amino, protected amino, C_1 to C_3 acyloxy, nitro, carboxy, protected carboxy, carbamoyl, carbamoyloxy, cyano, N-(methylsulfonylamino) or C_1 to C_4 alkoxy; and/or the phenyl group may be substituted with 1 or 2 groups chosen from halogen, hydroxy, protected hydroxy, nitro, C_1 to C_6 to alkyl, C_1 to C_4 alkoxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, aminomethyl, protected

aminomethyl, a N-(methylsulfonylamino) group, or a phenyl group, substituted or unsubstituted, for a resulting biphenyl group. When either the C₁ to C₆ alkyl portion or the phenyl portion or both are mono- or di-substituted
5 the substituents can be the same or different.

Examples of the term "C₁ to C₁₂ substituted phenylalkyl" include groups such as 2-phenyl-1-chloroethyl, 2-(4-methoxyphenyl)eth-1-yl, 2,6-dihydroxy-4-phenyl(n-hex-2-yl), 5-cyano-3-methoxy-2-phenyl(n-pent-
10 3-yl), 3-(2,6-dimethylphenyl)n-prop-1-yl, 4-chloro-3-aminobenzyl, 6-(4-methoxyphenyl)-3-carboxy(n-hex-1-yl), 5-(4-aminomethyl-phenyl)-3-(aminomethyl)(n-pent-2-yl), 5-phenyl-3-keto-(n-pent-1-yl), 4-(4-aminophenyl)-4-(1,4-oxetanyl)(n-but-1-yl), and the like.

15 The term "substituted phenyl" specifies a phenyl group substituted with one or more, and preferably one or two, moieties chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₁ to C₄ alkoxy, carboxy, protected carboxy,
20 carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino trifluoromethyl, N-(methylsulfonylamino), or phenyl, substituted or
25 unsubstituted, such that, for example, a biphenyl results.

Examples of the term "substituted phenyl" includes a mono- or di(halo)phenyl group such as 4-chlorophenyl, 2,6-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 3-chlorophenyl, 3-bromophenyl, 4-bromophenyl, 3,4-dibromophenyl, 3-chloro-4-fluorophenyl, 2-fluorophenyl and the like; a mono or di(hydroxy)phenyl groups such as 4-hydroxyphenyl, 3-hydroxyphenyl, 2,4-dihydroxyphenyl, the protected-hydroxy derivatives thereof and the like; a nitrophenyl group such as 3-or 4-nitrophenyl; a cyanophenyl group for example, 4-cyanophenyl; a mono- or di(lower alkyl)phenyl group such as 4-methylphenyl, 2,4-dimethylphenyl, 2-methylphenyl, 4-(iso-propyl)phenyl, 4-ethylphenyl, 3-(n-prop-1-yl)phenyl and the like; a mono or di(alkoxyl)phenyl group, for example, 2,6-dimethoxyphenyl, 4-methoxyphenyl, 3-ethoxyphenyl, 4-(isopropoxy)phenyl, 4-(t-butoxy)phenyl, 3-ethoxy-4-methoxyphenyl, 3-(4-methylphenoxy)phenyl, and the like; 3-or 4-trifluoromethylphenyl; a mono- or dicarboxyphenyl or (protected carboxy)phenyl group such as 4-carboxyphenyl or 2,4-di(protected carboxy)phenyl; a mono-or di(hydroxymethyl)phenyl or (protected hydroxymethyl)phenyl such as 3-(protected hydroxymethyl)phenyl or 3,4-di(hydroxymethyl)phenyl; a mono- or di(aminomethyl)phenyl or (protected aminomethyl)phenyl such as 2-(aminomethyl)phenyl or 2,4-(protected aminomethyl)phenyl; or a mono- or di(N-(methylsulfonylamino))phenyl such as 3-(N-(methylsulfonylamino))phenyl. Also, the term "substituted phenyl" represents disubstituted phenyl groups wherein the substituents are different, for example, 3-methyl-4-hydroxyphenyl, 3-chloro-4-

hydroxyphenyl, 2-methoxy-4-bromophenyl, 4-ethyl-2-hydroxyphenyl, 3-hydroxy-4-nitrophenyl, 2-hydroxy 4-chlorophenyl and the like.

The term "substituted naphthyl" specifies a
5 naphthyl group substituted with one or more, and preferably one or two, moieties chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₁ to C₄ alkoxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl,
10 hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino trifluoromethyl or N-(methylsulfonylamino).

The terms "halo" and "halogen" refer to the
15 fluoro, chloro, bromo or iodo groups.

The term "(monosubstituted)amino" refers to an amino group with one substituent chosen from the groups consisting of phenyl, substituted phenyl, C₁ to C₆ alkyl, and C₇ to C₁₂ arylalkyl, wherein the latter three
20 substituent terms are as defined above. The (monosubstituted)amino can additionally have an amino-protecting group as encompassed by the term "protected (monosubstituted)amino."

The term "(disubstituted)amino" refers to amino
25 groups with two substituents chosen from the group consisting of phenyl, substituted phenyl, C₁ to C₆ alkyl, and C₇ to C₁₂ arylalkyl wherein the latter three

substituent terms are as described above. The two substituents can be the same or different.

The term "amino-protecting group" as used herein refers to substituents of the amino group commonly employed to block or protect the amino functionality while reacting other functional groups on the amine component. The term "protected (monosubstituted) amino" means there is an amino-protecting group on the monosubstituted amino nitrogen atom. In addition, the term "protected carboxamide" means there is an amino-protecting group replacing the proton so that there is no N-alkylation. Examples of such amino-protecting groups include the formyl ("For") group, the trityl group, the phthalimido group, the trichloroacetyl group, the chloroacetyl, bromoacetyl, and iodoacetyl groups, urethane-type blocking groups, such as t-butoxy-carbonyl ("Boc"), 2-(4-biphenyl)propyl(2)oxycarbonyl ("Bpoc"), 2-phenylpropyl(2)oxycarbonyl ("Poc"), 2-(4-xenyl)isopropoxycarbonyl, 1,1-diphenylethyl(1)-oxycarbonyl, 1,1-diphenylpropyl(1)oxycarbonyl, 2-(3,5-dimethoxyphenyl)propyl(2)oxycarbonyl ("Ddz"), 2-(p-toluy)l)propyl(2)oxycarbonyl, cyclopentanyloxycarbonyl, 1-methylcyclopentanyloxycarbonyl, cyclohexanyloxy-carbonyl, 1-methylcyclohexanyloxycarbonyl, 2-methylcyclohexanyloxycarbonyl, 2-(4-toluy)sulfonyl)ethoxycarbonyl, 2-(methylsulfonyl)ethoxycarbonyl, 2-(triphenylphosphino)-ethoxycarbonyl, 9-fluoroenylmethoxycarbonyl ("Fmoc"), 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, 1-(trimethylsilylmethyl)prop-1-enyloxycarbonyl, 5-benz-

isoxalylmethoxycarbonyl, 4-acetoxybenzyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-ethynyl(2)propoxycarbonyl, cyclopropylmethoxycarbonyl, isobornyloxycarbonyl, 1-piperidyloxycarbonyl, benzyloxycarbonyl ("Z"), 4-phenylbenzyloxycarbonyl, 2-methylbenzyloxycarbonyl, α -2,4,5,-tetramethylbenzyloxycarbonyl ("Tmz"), 4-methoxybenzyloxycarbonyl, 4-fluorobenzyloxycarbonyl, 4-chlorobenzyloxycarbonyl, 3-chlorobenzyloxycarbonyl, 2-chlorobenzyloxycarbonyl, 2,4-dichlorobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 3-bromobenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-cyanobenzyloxycarbonyl, 4-(decyloxy)benzyloxycarbonyl, and the like; the benzoylmethylsulfonyl group, dithiasuccinoyl ("Dts"), the 2-(nitro)phenylsulfenyl group ("Nps"), the diphenylphosphine oxide group, and like amino-protecting groups. The species of amino-protecting group employed is not critical so long as the derivatized amino group is stable to the conditions of the subsequent reaction(s) and can be removed at the appropriate point without disrupting the remainder of the compounds. Preferred amino-protecting groups are Boc and Fmoc. Further examples of amino-protecting groups embraced to by the above term are well known in organic synthesis and the peptide art and are described by, for example, T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis," 2nd ed., John Wiley and Sons, New York, NY, 1991, Chapter 7, M. Bodanzsky, "Principles of Peptide Synthesis," 1st and 2nd revised ed., Springer-Verlag, New York, NY, 1984 and 1993, and Stewart and Young, "Solid Phase Peptide Synthesis," 2nd ed., Pierce Chemical Co., Rockford, IL, 1984, each of which is incorporated herein by reference.

The related term "protected amino" defines an amino group substituted with an amino-protecting group discussed above.

The term "carboxy-protecting group" as used
5 herein refers to one of the ester derivatives of the carboxylic acid group commonly employed to block or protect the carboxylic acid group while reactions are carried out on other functional groups on the compound. Examples of such carboxylic acid protecting groups
10 include 4-nitrobenzyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,4,6-trimethoxybenzyl, 2,4,6-trimethylbenzyl, pentamethylbenzyl, 3,4-methylenedioxybenzyl, benzhydryl, 4,4'-dimethoxytrityl, 4,4',4"-trimethoxytrityl, 2-
15 phenylprop-2-yl, trimethylsilyl, t-butyldimethylsilyl, 2,2,2-trichloroethyl, β -(trimethylsilyl)ethyl, β -(di(n-butyl)methylsilyl)ethyl, p-toluenesulfonylethyl, 4-nitrobenzyl-sulfonylethyl, allyl, cinnamyl, 1-(trimethylsilylmethyl)-prop-1-en-3-yl, and like moieties.
20 The species of carboxy-protecting group employed is not critical so long as the derivatized carboxylic acid is stable to the conditions of subsequent reaction(s) and can be removed at the appropriate point without disrupting the remainder of the molecule. Further
25 examples of these groups are found in E. Haslam, "Protective Groups in Organic Chemistry," J.G.W. McOmie, Ed., Plenum Press, New York, NY, 1973, Chapter 5, and T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis," 2nd ed., John Wiley and Sons, New
30 York, NY, 1991, Chapter 5, each of which is incorporated

herein by reference. A related term is "protected carboxy," which refers to a carboxy group substituted with one of the above carboxy-protecting groups.

The term "hydroxy-protecting group" refers to readily cleavable groups bonded to hydroxyl groups, such as the tetrahydropyranyl, 2-methoxyprop-2-yl, 1-ethoxyeth-1-yl, methoxymethyl, β -methoxyethoxymethyl, methylthiomethyl, t-butyl, t-amyl, trityl, 4-methoxytrityl, 4,4'-dimethoxytrityl, 4,4',4"-trimethoxytrityl, benzyl, allyl, trimethylsilyl, (t-butyl)dimethylsilyl and 2,2,2-trichloroethoxycarbonyl groups and the like. The species of hydroxy-protecting groups is not critical so long as the derivatized hydroxyl group is stable to the conditions of subsequent reaction(s) and can be removed at the appropriate point without disrupting the remainder of the quinazolinone molecule. Further examples of hydroxy-protecting groups are described by C.B. Reese and E. Haslam, "Protective Groups in Organic Chemistry," J.G.W. McOmie, Ed., Plenum Press, New York, NY, 1973, Chapters 3 and 4, respectively, and T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis," 2nd ed., John Wiley and Sons, New York, NY, 1991, Chapters 2 and 3.

The substituent term "C₁ to C₄ alkylthio" refers to sulfide groups such as methylthio, ethylthio, n-propylthio, iso-propylthio, n-butylthio, t-butylthio and like groups.

The substituent term "C₁ to C₄ alkylsulfoxide" indicates sulfoxide groups such as methylsulfoxide, ethylsulfoxide, n-propylsulfoxide, iso-propylsulfoxide, n-butylsulfoxide, sec-butylsulfoxide, and the like.

5 The term "C₁ to C₄ alkylsulfonyl" encompasses groups such as methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, iso-propylsulfonyl, n-butylsulfonyl, t-butylsulfonyl, and the like.

 Phenylthio, phenyl sulfoxide, and phenylsulfonyl
10 compounds are known in the art and these terms have their art recognized definition. By "substituted phenylthio," "substituted phenyl sulfoxide," and "substituted phenylsulfonyl" is meant that the phenyl can be substituted as described above in relation to
15 "substituted phenyl."

 The substituent terms "cyclic C₂ to C₁₀ alkylene," "substituted cyclic C₂ to C₁₀ alkylene," "cyclic C₂ to C₁₀ heteroalkylene," and "substituted cyclic C₂ to C₁₀ heteroalkylene," defines such a cyclic group
20 bonded ("fused") to the phenyl radical. The cyclic group may be saturated or contain one or two double bonds. Furthermore, the cyclic group may have one or two methylene groups replaced by one or two oxygen, nitrogen or sulfur atoms.

25 The cyclic alkylene or heteroalkylene group may be substituted once or twice by substituents selected from the group consisting of the following moieties:

hydroxy, protected hydroxy, carboxy, protected carboxy, keto, ketal, C₁ to C₄ alkoxycarbonyl, formyl, C₂ to C₄ alkanoyl, C₁ to C₆ alkyl, carbamoyl, C₁ to C₄ alkoxy, C₁ to C₄ alkylthio, C₁ to C₄ alkylsulfoxide, C₁ to C₄ alkylsulfonyl, halo, amino, protected amino, hydroxymethyl or a protected hydroxymethyl.

The cyclic alkylene or heteroalkylene group fused onto the benzene radical can contain two to ten ring members, but it preferably contains four to six members. Examples of such saturated cyclic groups are when the resultant bicyclic ring system is 2,3-dihydro-indanyl and a tetralin ring. When the cyclic groups are unsaturated, examples occur when the resultant bicyclic ring system is a naphthyl ring or indanyl. Examples of fused cyclic groups which each contain one oxygen atom and one or two double bonds are when the phenyl ring is fused to a furo, pyrano, dihydrofurano, or dihydropyrano ring. Examples of cyclic groups which each have one nitrogen atom and contain one or two double more double bonds are when the phenyl is fused to a pyridino or pyrano ring. Examples of cyclic groups which each have one sulfur atom and contain one or two double bonds are when the phenyl is fused to a thieno, thiopyrano, dihydrothieno or dihydrothiopyrano ring. Examples of cyclic groups which contain two heteroatoms selected from sulfur and nitrogen and one or two double bonds are when the phenyl ring is fused to a thiazolo, isothiazolo, dihydrothiazolo or dihydroisothiazolo ring. Examples of cyclic groups which contain two heteroatoms selected from oxygen and nitrogen and one or two double bonds are when

the benzene ring is fused to an oxazolo, isoxazolo, dihydrooxazolo or dihydroisoxazolo ring. Examples of cyclic groups which contain two nitrogen heteroatoms and one or two double bonds occur when the benzene ring is fused to a pyrazolo, imidazolo, dihydropyrazolo or dihydroimidazolo ring.

One or more of the quinazolinones or quinazolinone derivatives within a given library may be present as a pharmaceutically acceptable salt. The term "pharmaceutically-acceptable salt" encompasses those salts that form with the carboxylate anions and amine nitrogens and include salts formed with the organic and inorganic cations discussed below. Furthermore, the term includes salts that form by standard acid-base reactions with basic groups (such as amino groups) and organic or inorganic acids. Such acids include hydrochloric, sulfuric, phosphoric, acetic, succinic, citric lactic, maleic, fumaric, palmitic, cholic, pamoic, mucic, D-glutamic, d-camphoric, glutaric, phthalic, tartaric, lauric, stearic, salicyclic, methanesulfonic, benzenesulfonic, sorbic, picric, benzoic, cinnamic, and like acids.

The term "organic or inorganic cation" refers to counterions for the carboxylate anion of a carboxylate salt. The counter-ions are chosen from the alkali and alkaline earth metals, (such as lithium, sodium, potassium, barium and calcium); ammonium; and the organic cations (such as dibenzylammonium, benzylammonium, 2-hydroxyethylammonium, bis(2-hydroxyethyl)ammonium,


phenylethylbenzylammonium, dibenzylethylenediammonium, and like cations). Other cations encompassed by the above term include the protonated form of procaine, quinine and N-methylglucosamine, and the protonated forms of basic amino acids such as glycine, ornithine, histidine, phenylglycine, lysine and arginine. Furthermore, any zwitterionic form of the instant compounds formed by a carboxylic acid and an amino group is referred to by this term. For example, a cation for a carboxylate anion will exist when R_2 or R_1 is substituted with a (quaternary ammonium)methyl group. A preferred cation for the carboxylate anion is the sodium cation.

The compounds of the above Formulae can also exist as solvates and hydrates. Thus, these compounds may crystallize with, for example, waters of hydration, or one, a number of, or any fraction thereof of molecules of the mother liquor solvent. The solvates and hydrates of such compounds are included within the scope of this invention.

One or more quinazolinones or quinazolinone derivatives can be in the biologically active ester form, such as the non-toxic, metabolically-labile ester-form. Such ester forms induce increased blood levels and prolong the efficacy of the corresponding non-esterified forms of the compounds. Ester groups which can be used include the lower alkoxymethyl groups, for example, methoxymethyl, ethoxymethyl, iso-propoxymethyl and the like; the α -(C_1 to C_4) alkoxyethyl groups, for example methoxyethyl, ethoxyethyl, propoxyethyl, iso-propoxyethyl,

and the like; the 2-oxo-1,3-dioxolen-4-ylmethyl groups, such as 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl, 5-phenyl-2-oxo-1,3-dioxolen-4-ylmethyl, and the like; the C₁ to C₃ alkylthiomethyl groups, for example methylthiomethyl, ethylthiomethyl, iso-propylthiomethyl, and the like; the acyloxymethyl groups, for example pivaloyloxymethyl, pivaloyloxyethyl, α-acetoxymethyl, and the like; the ethoxycarbonyl-1-methyl group; the α-acetoxyethyl; the 3-phthalidyl or 5,6-dimethylphthalidyl groups; the 1-(C₁ to C₄ alkyloxycarbonyloxy)ethyl groups such as the 1-(ethoxycarbonyloxy)ethyl group; and the 1-(C₁ to C₄ alkylaminocarbonyloxy)ethyl groups such as the 1-(methylaminocarbonyloxy)ethyl group.

The quinazolinone library of Formula I can be prepared, using either solution or solid-phase techniques, by combining and reacting an anthranilic acid and an amine component according to the general Reaction Scheme I:




The substituents R^1 , R^2 , R^3 , and Y in Reaction Scheme I have the same meanings as those described above.

As in the above Reaction Scheme I, the amino nitrogen of anthranilic acid can be, though need not be, acylated. Alternatively, the amine component, H_2N-R^1-Y , can be acylated as discussed in more detail below. Where acylated, the anthranilic acid is acylated with any of the above defined R^3 groups. Examples of anthranilic acids, include, but are not limited to, N-(acetyl)anthranilic acid, 3,5-dichloro-N-(acetyl)-anthranilic acid, 3,5-dibromo-N-(acetyl)anthranilic acid, 4,5-difluoro-N-(acetyl)-anthranilic acid, 3,5-dimethyl-N-(acetyl)anthranilic acid, 4-nitro-N-(acetyl)anthranilic acid, and 5-hydroxy-N-(acetyl)anthranilic acid, 3-methoxyanthranilic acid and 3-ethoxyanthranilic acid. The anthranilic acid is preferably acylated and, more preferably, acetylated (R^3 is methyl). Preferred acetylated anthranilic acids are N-(acetyl)anthranilic acid, 3,5-dichloro-N-(acetyl)-anthranilic acid, 3,5-dibromo-N-(acetyl)anthranilic acid, 4,5-difluoro-N-(acetyl)-anthranilic acid, 3,5-dimethyl-N-(acetyl)anthranilic acid, and 5-hydroxy-N-(acetyl)anthranilic acid.

Solid-phase techniques may be employed to condense anthranilic acid and the amine component, H_2N-R^1-Y , of Reaction Scheme I whereby the anthranilic acid is resin bound. For instance, the carboxylic acid functionality of an acylated anthranilic acid can be coupled to resin bound amines and subsequently condensed

at 130°C with the amine component in xylene. Various amino resins are discussed in greater detail below. Alternatively, linkage of the compound to the solid support can be through the anthranilic acid component
5 using aminoterephthalic acid and the like under condensing conditions similar to those discussed in further detail below.

Where anthranilic acid derivatives are used in the preparation of quinazolinones as described above, the
10 starting material, and hence the resulting quinazolinone, is based on a benzene ring. However, quinazolinones can, alternatively, be based on other ring systems, and in particular on heterocyclic rings having the structure of Formula VI:



In the above Formula VI, R^1 , R^2 , R^3 , and Y are as defined above and Z is a heteroaromatic ring having from two to six carbons and one or two heteroatoms selected from the group consisting of nitrogen, sulfur and oxygen. Examples of Z ring systems include pyridino,
5 pyrimidino, pyrazino, and pyridazino.

Preferred alternative starting materials to anthranilic acid which provide different ring systems than phenyl include pyridine, such as 2-aminonicotinic
10 acid, and pyrazine, such as 3-aminopyrazine-2-carboxylic acid.

The additional starting material of Reaction Scheme I, the amine component H_2N-R^1-Y , can be a variety of amines, including aniline derivatives, aliphatic
15 amines, and amino carboxylic acids such as amino acids and aminophenyl carboxylic acids; each of which will be discussed in turn below.

Aniline compounds which can be used as the amine component include, for example, o-toluidine, 4-chloro-2-
20 methylaniline and 2-chloroaniline, and others well known in the art which are readily available or which can easily be synthesized. Where the quinazolinone library is made by combining and reacting anthranilic acid and an aniline, a solution phase reaction generally involves
25 pyrolytically condensing the reactants at approximately 180-190°C for about 15 minutes under inert atmosphere either as a melt or in any variety of polar aprotic solvents, such as sulfolane, dimethylformamide (DMF), or

1-methyl-2-pyrrolidinone (NMP). Example I below provides further illustration. Where the reaction is carried out in solution phase, generally equimolar amounts or other defined amounts of reactants are use. Again, the
5 reaction can done by solid-phase techniques as described above and in such instances excess reactants are used. In addition, condensation using various drying agents, such as phosphorus trichloride (PCl_3), phosphorus oxychloride (POCl_3), or phosphorus pentoxide (P_2O_5), in
10 toluene can be done at lower temperatures.

In instances where the anthranilic acid is not acylated as described above, aniline can alternatively be acylated. For example, Acetanilide or N-(acetyl)-toluidine can be used. The same reaction conditions as
15 with non-acylated aniline apply, except that the reaction generally takes up to two hours.

Alternatively, as described above, the amine component, $\text{H}_2\text{N-R}^1\text{-Y}$, of Reaction Scheme I can be an aliphatic amine. Aliphatic amines can be condensed with
20 anthranilic acid under generally the same conditions as used when condensing the aniline compounds.

The amine component of Reaction Scheme I can also be an amino carboxylic acid, including amino acids and aminophenyl carboxylic acids. The amino acid can be
25 any one of the twenty naturally-occurring amino acids or the D-form of any one of the naturally-occurring amino acids. In addition, the invention includes the use of non-naturally occurring amino acids, such as norleucine

("Nle"), norvaline ("Nva"), β -Ala, L- or D-naphthalanine, ornithine ("Orn"), homoarginine (homoArg) and others well known in the peptide art, such as those described in M. Bodanzsky, "Principles of Peptide Synthesis," 1st and 2nd revised ed., Springer-Verlag, New York, NY, 1984 and 5 1993, and Stewart and Young, "Solid Phase Peptide Synthesis," 2nd ed., Pierce Chemical Co., Rockford, IL, 1984, both of which are incorporated herein by reference. Amino acids and amino acid analogs can be purchased 10 commercially (Sigma Chemical Co.; Advanced Chemtec) or synthesized using methods known in the art.

The amino acids are indicated herein by either their full name or by the commonly known three letter code. Further, in the naming of amino acids, "D-" 15 designates an amino acid having the "D" configuration, as opposed to the naturally occurring L-amino acids. Where no specific configuration is indicated, one skilled in the art would understand the amino acid to be an L-amino acid. The amino acids can, however, also be in racemic 20 mixtures of the D- and L-configuration.

As used herein, the phrase "any one of the twenty naturally-occurring amino acids" means any one of the following: Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, 25 and Val. As used herein, the language "the D-form of a naturally-occurring amino acid" means the D-isomer of any one of these naturally-occurring amino acids, with the exception of Gly, which does not occur as D or L isomers.

Preferred amino acids are L- and D-Ala, L- and D-Phe, Gly, L- and D-Ile, L- and D-Leu, L- and D-Arg, L- and D-Ser, L- and D-Thr, L- and D-Val, L- and D-Tyr, L-Nle, L-Nva, β -Ala, L- and D-naphthylalanine. When these
5 preferred amino acids are used, R¹ is preferably the α -carbon and the side chain of these respective amino acid as provided above in Table I.

Alternative preferred aminocarboxylic acids beside the above described amino acids include 7-
10 aminoheptanoic acid, L- α -aminobutyric acid, γ -aminobutyric acid, ϵ -aminocaproic acid, and aminophenyl carboxylic acids, such as 4-aminobenzoic acid, 4-aminophenylacetic acid, 4-aminophenylbutyric acid, 3-aminophenylacetic acid, 3-amino-2-methylbenzoic acid, 4-
15 amino-2-chlorobenzoic acid, 4-aminosalicylic acid.


When aminocarboxylic acids are used as the amine component, the method of synthesizing the quinazolinones is most usually and practically conducted using a solid-support. However, there is no reason the
20 synthesis cannot be done in solution phase. Resins which can serve as solid supports are well known in the art and include amino resins and hydroxy resins which are polymers crosslinked with amino and hydroxy groups, respectively. Such resins include 4-
25 methylbenzhydrylamine (MBHA), 4-methylbenzhydrylamine-copoly(styrene-1% divinylbenzene), 4-(oxymethyl)-phenylacetamido methyl (Pam), 4-(oxymethyl)-phenylacetamido methyl-copoly(styrene-1% divinylbenzene), 4-(hydroxymethyl)phenoxymethyl-copoly(styrene-1%

divinylbenzene) (Wang resin), all of which are commercially available, or to *p*-nitrobenzophenone oxime polymer (oxime resin), which can be synthesized as described by De Grado and Kaiser, J. Org. Chem., 47:3258 (1982), which is incorporated herein by reference. Recently, a polyethylene-grafted cross-linked polystyrene resin termed TentaGel has been made commercially available by RappPolymere (Tubingen, Germany), which resin can also be used with the present invention. These and other types of resins well known in the art can be used in the subject invention.

The amino carboxylic acid can be attached to the resin by coupling procedures well known in the art and as described in the ensuing Examples. During such attachment to the resin, at least the α -amino group of an amino acid, as well as the α -amino of other amino carboxylic acids, is protected with an amino-protecting group. However, with the relatively non-nucleophilic anilino group of an aminophenyl carboxylic acid, protection is not required. Where necessary, side chain functional groups of amino acids are also protected as is commonly done in the field. Prior to condensation of the amino carboxylic acid with anthranilic acid, at least the α -amino protecting group is removed with, for example, trifluoroacetic acid (TFA) for the removal of the Boc group and piperidine for the removal of the Fmoc group. The condensation reaction can be done under the same conditions as those described above and as provided in Example II.

Once the initial quinazolinone structure of Formula I is prepared by any one of the above described methods the quinazolinone mixture can be further chemically transformed to extend the range and chemical diversity of the compounds. Using the "libraries from libraries" concept, as described in Ostresh et al., Proc. Natl. Acad. Sci., 91:11138-11142 (1994), various libraries of quinazolinone derivatives can be prepared by chemically altering the initial quinazolinone library.

One such chemical transformation is to convert the quinazolinone library to a library of five or more styryl derivatives of quinazolinone having the Formula II:




Styryl derivatives can be prepared by treating the quinazolinone product with a non-nucleophilic base under anhydrous condition with lithium t-butoxide in tetrahydrofuran (LiOtBu/THF) for approximately 15 min., followed by adding a non-enolizable aldehyde. The aldehyde can be any one which results in R⁴ as described above. Exemplary aldehydes include 2,4-

- dichlorobenzaldehyde, 4-hydroxybenzaldehyde, 2-naphthaldehyde, 2,5-dimethylbenzaldehyde, 3,4-difluorobenzaldehyde, 4-bromobenzaldehyde, 3-(4-methylphenoxy)benzaldehyde, para-(anisaldehyde), 3-ethoxy-4-hydroxybenzaldehyde, 4-biphenylcarboxaldehyde, 4-nitrobenzaldehyde, benzaldehyde, 10-chloro-9-anthraldehyde, 6-methyl-2-pyridinecarboxaldehyde, 2-methoxy-1-naphthaldehyde, 2,4,5-trimethoxybenzaldehyde, 4-(dimethylamino)benzaldehyde, and 2-butylacrolein.
- Preferred aldehydes are 2,4-dichlorobenzaldehyde, 2-naphthaldehyde, 2,5-dimethylbenzaldehyde, 3,4-difluorobenzaldehyde, 4-bromobenzaldehyde, 3-(4-methylphenoxy)benzaldehyde, para-(anisaldehyde), 4-biphenylcarboxaldehyde, benzaldehyde, 6-methyl-2-pyridinecarboxaldehyde, 2-methoxy-1-naphthaldehyde, 2,4,5-trimethoxybenzaldehyde, and 4-(dimethylamino)benzaldehyde.


The library of styrene derivatives itself can be further chemically altered. For example, the styrene derivatives can be epoxidized with peroxyacids, such as *m*-chloroperbenzoic acid. Alternatively, or in addition thereto, the carbonyl can be reduced by standard procedures, for example, by reduction with lithium aluminum hydride (LiAlH_4) in THF. Similarly, the styrene compounds can be N-alkylated as described below.

In another embodiment of the present invention, the quinazolinone library can be reduced with, for example, a borohydride reagent under the usual

conditions, to prepare a library five or more
quinazolinone derivatives of Formula III:




Alternatively, or in addition thereto, in yet
5 another embodiment of the invention, the basic amine of
the quinazolinones can be alkylated to prepare a library
of compounds of Formula IV:



To prepare these or related N-alkylated
10 derivatives, the amine is first reduced with a
borohydride reagent, followed by alkylation with
alkylating agents of the R⁵ groups described above. Such
alkylating agents include R⁵ groups derivatized with a

bromo, iodo, triflate or methylsulfonate groups. Other alkylating derivatives of the R^5 group are well known. Finally, the compounds are reoxidized to obtain the quaternary amine using dichlorodicyanoquinone (DDQ).

- 5 An alternative approach to obtain libraries of much larger diversity, without having to form styrene derivatives as described above, is to use N-(2-bromoacetyl)anthranilic acid and two amine components, such as two anilines, as provided in Reaction Scheme II:



- 10 In Reaction Scheme II, R^1 , R^2 , and R^6 are as defined above. The substituent X is a leaving group, such as bromo, iodo, triflate, methylsulfonate, or phenylsulfonate. The first amine component can be condensed with, for example, N-(bromoacetyl)anthranilic
15 acid in sulfolane at 35°C for one hour. N-

(bromoacetyl)anthranilic can be prepared by acylating anthranilic acid with bromoacetyl chloride. Generally, to ensure that a tertiary amine does not result the first amine component is protected with an amino-protecting group, such as Didyl. The second amine component, such as a second aniline, can be condensed in sulfolane at approximately 200°C for about two hours.

Approaches for preparing the libraries of quinazolinones or quinazolinone derivatives are several and can be any of those well known in the art. For example, preparation of the libraries can be by the "split synthesis" method, as described in Gallop et al., J. Med. Chem., 37:1233-1251 (1994). The split synthesis procedure involves dividing a resin support into n equal fractions, in a separate reaction carry out a single reaction to each aliquot, and then thoroughly mixing all the resin particles together. Repeating the protocol for a total of x cycles can produce a stochastic collection of up to n^x different compounds. For instance, in Example II the split synthesis approach was used to prepare a mixture of thirty five aminocarboxylic acids. An alternative format is, preparing sublibraries in the $O_1O_2X_1$ format, wherein two positions on the compounds, O_1 and O_2 , are explicitly defined and a third position, X_1 , varies. Such sublibraries can be conveniently prepared by the tea-bag technique, as is known in the art, and described, for example in U.S. Patent No. 4,631,211 to Houghten and Houghten et al., Proc. Natl. Acad. Sci., 82:5131-5135 (1985), as well as described in Example II. Alternatively, or in addition thereto, the iterative

selection and enhancement process of screening and sublibrary resynthesis can be employed. For example, a sublibrary of various R^1 substituents can be screened to select the most active R^1 substituent. The quinazolinone
5 having the most active R^1 is then resynthesized and with the R^1 position being defined, a new R^2 position mixture library is prepared, screened, and the most active R^2 selected. The above process can then be repeated to identify R^3 and the other most active R substituents on
10 the quinazolinone ring. In yet another approach, the positional scanning technique, only a single position is defined in a given sublibrary and the most preferred substituent at each position of the compound is identified.

15 The advantage of synthetic combinatorial libraries (SCLs) made up of mixtures of tens of millions of different compounds is that they can be used to rapidly identify individual, active compounds without the need to individually synthesize, purify, and test every
20 single compound. Since the libraries are in solution (i.e., not attached to a bead, pin, phage, glass, etc.) they can be screened in virtually any assay system. Here, the libraries can be screened in a variety of described, for example, in Parmar and Seth, Canadian J. Of Biochem., 43:1179-1185 (1965), Joshi et al., Ind. J. Exp. Biol., 15:1064-1066 (1977), Leszkovszky et al., Aeta Physiologica, 6:81-90, Gujral et al., Ind. J. Med. Res., 45:207-211 (1957), all of which are incorporated herein
25 by reference.


The following Examples are intended to illustrate but not limit the present invention.

EXAMPLE I

SOLUTION-PHASE PREPARATION OF A QUINAZOLINONE LIBRARY


5 This Example provides a solution-phase combinatorial synthesis of a quinazolinone library.

 Following the below Reaction Scheme III, in solution phase, N-acetyl anthranilic acids were condensed with aniline compounds to prepare a library of
10 quinazolinones.




 Specifically, in a single 10 ml test tube, 1.5
equimolar (Eq) each of two different N-(acetyl)
anthranilic acids, N-(acetyl)anthranilic acid (1336 mg;
1.5 Eq) and 3,5-dichloro-N-(acetyl)anthranilic acid
15 (1860; 1.5 Eq) (identified below as 1 and 2,
respectively), were combined and pyrolytically condensed
for 15 min. at 180-190°C with one equimolar amount each
of three aniline compounds, o-toluidine (536 μl; 1 Eq),


4-chloro-2-methylaniline (597 μ l; 1 Eq) and 2-chloroaniline (525 μ l; 1 Eq) (identified below as 3, 4 and 5, respectively).




(1)




(2)



(3)



(4)



(5)


RP-HPLC purification (Beckman System Gold, Los Angeles, CA; reverse-phase, acetonitrile/TFA system) and Matrix Assisted Laser Desorption Ionization-Mass Spectrometry (MALDI-MS) (Cratos, Columbia, MD) showed the presence of the six expected quinazolinone products as well as starting material.

EXAMPLE II



SOLID-PHASE PREPARATION OF STYRYL DERIVATIVES OF QUINAZOLINONE

This Example provides a solid-phase
 5 combinatorial synthesis of a library containing
 approximately 3000 styryl derivatives of quinazolinones.

1. This Example follows the general Reaction
 Scheme IV as follow:



10



In Reaction Scheme IV, R^1 , R^2 , R^3 , and R^4 are the respective R groups based on the starting materials provided in Table II below. The P group is an amino-protecting group as defined above.

- 5 As shown by Reaction Scheme IV, preparation of the library containing styryl derivatives of quinazolinones involved the following steps. Briefly, first, thirty five diverse amino carboxylic acids, varying at R^1 and including various Boc-protected amino
- 10 acids (Boc-AAs) and differing aminophenyl carboxylic acids, were coupled to MBHA resin. The resins were then mixed, followed by condensation of seven acetylated anthranilic acids, each differing by their R^2 substituent, to the mixtures of resin bound amino carboxylic acids.
- 15 Third, the resulting quinazolinone product was treated with LiOtBu/THF and thirteen different benzaldehydes having differing R^4 groups were added to arrive at a library of approximately 3000 styryl derivatives of quinazolinone. Finally, the compounds were cleaved from
- 20 the MBHA resin and tested for biological activity.

The library was prepared in the $O_3O_2X_1$ format in which there were 91 mixtures of 35 compounds. The starting materials used are listed in Table II.

TABLE II

TABLE II			
#	ALDEHYDE	ANTHRANILIC ACID DERIVATIVE	AMINO CARBOXYLIC ACID
1	2,4-DICHLOROBENZALDEHYDE	ANTHRANILIC ACID	BOC-L-ALANINE
2			BOC-L-PHENYALANINE
3	2-NAPHTHALDEHYDE	3,5-DICHLOROANTHRANILIC ACID	BOC-GLYCINE
4	2,5-DIMETHYLBENZALDEHYDE	3,5-DIBROMOANTHRANILIC ACID	BOC-L-ISOLEUCINE
5	3,4-DIFLUOROBENZALDEHYDE	3,5-DIMETHYLANTHRANILIC ACID	BOC-L-LEUCINE
6	4-BROMOBENZALDEHYDE	4,5-DIFLUOROANTHRANILIC ACID	BOC-L-ARGININE
7	3-(4-METHYLPHENOXY) BENZALDEHYDE	5-HYDROXYANTHRANILIC ACID	BOC-L-SERINE
8	PARA-ANISALDEHYDE	3-AMINO-2-NAPHTHOIC ACID	BOC-L-THREONINE
9			BOC-L-VALINE
10	4-BIPHENYLCARBOXALDEHYDE		BOC-L-TYROSINE
11			BOC-D-ALANINE
12	BENZALDEHYDE		BOC-D-PHENYLALANINE
13			BOC-D-ISOLEUCINE
14	6-METHYL-2-PYRIDINECARBOXALDEHYDE		BOC-D-LEUCINE

TABLE II

#	ALDEHYDE	ANTHRANILIC ACID DERIVATIVE	AMINO CARBOXYLIC ACID
15	2-METHOXY-1-NAPHTHALDEHYDE		AMINO CARBOXYLIC ACID
16	2,4,5-TRIMETHOXY BENZALDEHYDE		BOC-D-ARGININE
17	4-(DIMETHYLAMINO) BENZALDEHYDE		BOC-D-SERINE
18			BOC-D-THREONINE
19			BOC-D-VALINE
20			BOC-D-TYROSINE
21			BOC-L-NORLEUCINE
22			BOC-L-NORVALINE
23			BOC- β -ALANINE
24			BOC-L- α -AMINO BUTYRIC ACID
25			BOC- γ -AMINO BUTYRIC ACID
26			BOC-e-AMINOCAPROIC ACID
27			BOC-L-NAPHTHYLALANINE
28			BOC-D-NAPHTHYLALANINE
29			BOC-7-AMINOHEPTANOIC ACID
			4-AMINO BENZOIC ACID

TABLE II

TABLE II		
#	ALDEHYDE	ANTHRANILIC ACID DERIVATIVE
30		AMINO CARBOXYLIC ACID
31		4-AMINOPHENYLACETIC ACID
32		4-AMINOPHENYLBUTYRIC ACID
33		3-AMINOPHENYLACETIC ACID
34		3-AMINO-2-METHYLBENZOIC ACID
35		4-AMINO-2-CHLOROBENZOIC ACID
		4-AMINOSALICYLIC ACID

1. Coupling of Amino Carboxylic Acids to MBHA Resin

The thirty five diverse amino carboxylic acid provided in Table II, varying at R¹ and including various Boc-AAs and differing aminophenyl carboxylic acids, were coupled to MBHA resin as follows.

Thirty five polypropylene mesh packets (T-bags, ~2" square, 65 μ ; McMaster Carr, Chicago, IL) of (0.6 g, 0.93 meq/g) MBHA resin were prepared, washed with dichloromethane (DCM) (2X, ~ 5 ml each), neutralized with 5% diisopropylethylamine/DCM (3X, ~ 5 ml each), and washed with DCM (2X, ~ 5 ml each). Each resin packet was individually coupled overnight (~ 16 hr. except for Gly, 1 hr.) by adding 10X amino acid in DCM (0.2 M) or aminophenylcarboxylic acid in dimethylformamide (DMF) followed by diisopropylcarbodiimide/DCM (10X, 0.2 M) for a final concentration of 0.1 M. 5% DMF was used to solubilize the Arg and Ser derivatives. N-hydroxybenzotriazole (HOBt; 10X) was added to the aminophenyl carboxylic acids couplings. The relatively non-nucleophilic anilino groups of the aminophenylcarboxylic acids were unprotected. Following coupling completion, resin packets were washed with DCM (1X), isopropanol (IPA) (2X), and DCM (2X). The amino acid was deprotected with 55% TFA in DCM. Each packet was then opened and the resin carefully washed into a common vessel using alternating DCM and MeOH washes (final volume, ~ 200 ml). The resin was mixed using a magnetic stir bar for 2.5 hr. The resin was then

filtered, washed with MeOH, and dried under vacuum. Based upon synthesis and cleavage, for each of the thirty five aminocarboxylic acids reaction completion was >95%.

5 2. Quinazolinone Library by Condensation of Acetylated Anthranilic Acids to the Mixture of Resin Bound Amino Carboxylic Acids

Seven acetylated anthranilic acids, each differing by their R² substituent and listed in Table II, were condensed to the above prepared mixture of resin
10 bound Boc-AAs and aminophenylcarboxylic acids.

a. Acetylation of the Anthranilic Acids

Each anthranilic acid listed in Table II was first acetylated. Five to ten grams of each acetylated anthranilic acid was prepared by adding 1.5X neat acetic
15 anhydride (Ac₂O) to 0.2 M anthranilic acid/THF and allowing the reaction to proceed at room temperature for 1 hr. Following addition of an equal volume of IPA, the solution was evaporated to dryness on a rotary
evaporator, redissolved and evaporated from IPA, followed
20 by THF. Reaction completion was confirmed by RP-HPLC and MALDI-MS.

b. Condensation Reaction

Each acetylated anthranilic acid (5X) in sulfolane (~0.4 M, tetramethylene sulfone, 35°C, 10 ml
25 each) was added to the amino acid/aminophenyl carboxylic

acid resin mixtures (1 g) in individual 50 ml Kimax tubes and heated at 190°C for 2 hr. Each resin was then washed by filtration with DMF (2X), MeOH (1X), DMF (2X), MeOH (1X), DMF (2X), MeOH (1X), DMF (2X). Resins were then
5 washed with MeOH and dried under high vacuum.

Individual controls included the following. As representative of the amino acids, resin-bound phenylalanine was condensed with each anthranilic acid,
10 the products were cleaved and analyzed by HPLC and MS. As representative of the aminophenylcarboxylic acids, each of the resin-bound aminophenylcarboxylic acids was condensed with N-(acetyl)anthranilic acid. Products were removed from resin and analyzed. Using the same
15 instruments and conditions as above, RP-HPLC and MALDI-MS of individual control compounds indicated that compounds of 60-95% purity were formed and in all cases the expected product was the major component.

3. Styryl Derivatives of the Quinazolinones

20 From the above made library of quinazolinones a library of styryl derivatives of quinazolinone were prepared as follows.

a. Preparation of Aldehyde

Stock solutions of each aldehyde listed in
25 Table II were prepared based upon the use of seven 50 mg

packets of resin for each benzaldehyde. 100X over resin substitution was added to 25 ml THF in 50 ml Kimax tubes. Anhydrous MgSO_4 (2-5 g) was added to each tube, followed by capping. Following centrifugation, $\frac{1}{2}$ of the solution
5 was removed (in a glovebox under nitrogen atmosphere) for use in the reaction.

b. Styryl Derivatization

Ninety-one mesh packets (13 packets - one per benzaldehyde - for each of the seven OX resins)
10 containing 50 mg resin were prepared. To each set of 7 packets in 50 ml KIMAX tubes, LiOtBu in THF (10X, 0.2 M) was added under anhydrous conditions and allowed to react for 15 min. Following washes with anhydrous THF (2X),
aldehyde stock solution (12.5 ml, 50X over resin
15 substitution) and LiOtBu (10X, 1 M) were added. The tubes were capped and placed in a 70°C oil bath overnight (~16 hr.). The resin packets were then washed with DMF (1X), DCM (2X), followed by 5 alternating washes of DMF and MeOH. The packets were dried under high vacuum,
20 followed by treatment with hydrogen fluoride (5% anisole, 1 hr., 0°C) to cleave compounds from the MBHA resin.

As a control for the aldehyde condensation, the following was done. For each aldehyde two quinazolinone resins were added to each reaction vessel to monitor the
25 condensation. The two quinazolinone resins were the result of (1) resin-bound aminophenyl acetic acid condensed with N-(acetyl)anthranilic acid and (2) resin-

bound phenylalanine condensed with N-(acetyl)anthranilic acid. Resins were cleaved and products analyzed by HPLC and MS. In addition, a post library control was done. This control confirmed that the procedure used to add the
5 aldehyde, and in particular the addition of base, did not affect the aminocarboxylic acids used in the library. Resins were made of each of the thirty five and aminocarboxylic acids used in the library. The resins were then condensed, first, with N-(Acetyl)anthranilic
10 acid and then with 6-Methyl-2-pyridine carboxaldehyde. Upon cleavage from resin, products were analyzed by HPLC and MS.

Percent yields based upon starting resin substitution are listed in Table III. Reference numbers
15 ("REF. #") in Table III first reference the aldehyde number provided in starting materials Table II, followed by the anthranilic acid derivative number also provided in Table II. For example, "1-1" hereinbelow in Table III means the yields for the reactants 2,4-Dichlorobenz-
20 aldehyde, N-(acetyl)anthranilic acid and each of the thirty five amino carboxylic acids of Table II. Similarly, reference number "6-3" means 4-Bromobenzaldehyde, 3,5-Dichloroanthranilic acid and the thirty five amino carboxylic acids.

TABLE III								
REF. #	EXP. YD.	THEO. YD.	% YD.		REF. #	EXP. YD.	THEO. YD.	% YD.
1-1	8.7	15.7	55.4		10-5	9.2	16.7	55.1
3-1	10.6	15.1	70.2		12-5	7.8	14.0	55.7
4-1	10.1	14.3	70.6		14-5	13.3	14.5	91.7
5-1	10.2	14.6	69.9		15-5	11.6	16.8	69.0
6-1	13.7	16.1	85.1		16-5	13.0	17.2	75.6
7-1	11.6	17.1	67.8		17-5	12.3	15.5	79.4
8-1	11.9	14.3	83.2		1-6	7.2	16.6	43.4
10-1	11.1	16.0	69.4		3-6	7.5	15.9	47.2
12-1	9.8	13.3	73.7		4-6	9.2	15.2	60.5
14-1	13.2	13.8	95.7		5-6	10.0	15.4	64.9
15-1	12.3	16.1	76.4		6-6	9.7	16.9	57.4
16-1	12.6	16.5	76.4		7-6	8.4	17.9	46.9
17-1	9.6	14.8	64.9		8-6	12.4	15.2	81.6
1-3	5.8	17.4	33.3		10-6	12.2	16.8	72.6
3-3	6.7	16.7	40.1		12-6	10.5	14.2	73.9
4-3	6.3	16.0	39.4		14-6	14.7	14.7	100.0
5-3	6.4	16.2	39.5		15-6	10.8	17.0	63.5
6-3	5.0	17.7	28.2		16-6	11.8	17.3	68.2
7-3	6.9	18.6	37.1		17-6	12.5	15.7	79.6
8-3	6.7	16.0	41.9		1-7	13.5	16.1	83.9
10-3	6.5	17.6	36.9		3-7	12.2	15.5	78.7
12-3	5.3	15.0	35.3		4-7	11.7	14.7	79.6
14-3	11.3	15.5	72.9		5-7	12.8	15.9	85.3
15-3	7.8	17.7	44.1		6-7	11.3	16.5	68.5

TABLE III


REF. #	EXP. YD.	THEO. YD.	% YD.		REF. #	EXP. YD.	THEO. YD.	% YD.
16-3	7.0	18.1	38.7		7-7	13.1	17.4	75.3
17-3	9.2	16.5	55.8		8-7	13.4	14.7	91.2
1-4	5.4	19.2	28.1		10-7	10.1	16.4	61.6
3-4	4.8	18.6	25.8		12-7	9.9	13.7	72.3
4-4	4.8	17.9	26.8		14-7	11.3	14.2	79.6
5-4	5.2	18.2	28.6		15-7	12.6	16.5	76.4
6-4	4.9	19.5	25.1		16-7	11.2	16.9	66.3
7-4	6.3	20.4	30.9		17-7	12.8	15.2	84.2
8-4	6.4	18.0	35.6		1-8	9.0	16.9	53.3
10-4	4.0	19.5	20.5		3-8	10.6	16.3	65.0
12-4	5.5	17.0	32.4		4-8	14.4	15.5	92.9
14-4	10.4	17.5	59.4		5-8	11.4	15.8	72.2
15-4	7.5	19.6	38.3		6-8	7.7	17.3	44.5
16-4	7.7	19.9	38.7		7-8	7.6	18.2	41.8
17-4	10.2	18.4	55.4		8-8	9.4	15.6	60.3
1-5	8.6	16.4	52.4		10-8	8.9	17.2	51.7
3-5	8.6	15.7	54.8		12-8	9.5	14.5	65.5
4-5	8.2	15.0	54.7		14-8	12.6	15.1	83.4
5-5	11.0	15.3	71.9		15-8	12.7	17.3	73.4
6-5	10.5	16.8	62.5		16-8	13.6	17.7	76.8
7-5	11.1	17.7	62.7		17-8	11.1	16.0	69.4
8-5	10.6	15.0	70.7					

As can be seen from Table III, approximately 3,000 styryl derivatives of quinazolinone, a library from a library, were successfully prepared with reasonable yields.

5 Although the invention has been described with reference to the examples provided above, it should be understood that various modifications can be made by those skilled in the art without departing from the invention. Accordingly, the invention is set out in the
10 following claims.

WE CLAIM:

1. A library of quinazolinones comprising a mixture of five or more quinazolinones of the structure:



wherein:

- 5 R¹ is selected from the group consisting of a hydrogen atom, C₁ to C₆ alkyl; C₁ to C₆ substituted alkyl, C₇ to C₁₂ phenylalkyl, C₇ to C₁₂ substituted phenylalkyl, phenyl, substituted phenyl, C₃ to C₇ cycloalkyl, and C₃ to C₇ substituted cycloalkyl;
- 10 R² is selected from the group consisting of a hydrogen atom, halo, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₂ to C₇ alkenyl, C₂ to C₇ alkynyl, C₁ to C₆ substituted alkyl, C₂ to C₇ substituted alkenyl, C₂ to C₇ substituted alkynyl, C₁ to C₄ alkoxy, C₁ to C₇ acyloxy, C₁ to C₇ acyl, C₃ to C₇ cycloalkyl, C₃ to C₇ substituted cycloalkyl, C₃ to C₇ cycloalkenyl, C₃ to C₇ substituted cycloalkenyl, a heterocyclic ring, C₇ to C₁₂ phenylalkyl, C₇ to C₁₂ substituted phenylalkyl,
- 15

phenyl, substituted phenyl, cyclic C₂ to C₁₀ alkylene,
substituted cyclic C₂ to C₁₀ alkylene, cyclic C₂ to C₁₀
heteroalkylene, substituted cyclic C₂ to C₁₀
heteroalkylene, carboxy, protected carboxy,
5 hydroxymethyl, protected hydroxymethyl,
(monosubstituted)amino, protected
(monosubstituted)amino, (disubstituted)amino,
carboxamide, protected carboxamide, C₁ to C₄ alkylthio,
C₁ to C₄ alkylsulfonyl, methylsulfonylamino, C₁ to C₄
10 alkylsulfoxide, phenylthio, substituted phenylthio,
phenylsulfoxide, substituted phenylsulfoxide,
phenylsulfonyl, and substituted phenylsulfonyl;

R³ is selected from the group consisting of C₁ to C₆
alkyl, C₂ to C₇ alkenyl, C₂ to C₇ alkynyl, C₁ to C₆
15 substituted alkyl, C₂ to C₇ substituted alkenyl, C₂ to
C₇ substituted alkynyl, C₃ to C₇ cycloalkyl, C₃ to C₇
substituted cycloalkyl, C₇ to C₁₂ phenylalkyl, C₇ to C₁₂
substituted phenylalkyl, phenyl, and substituted
phenyl;

20 Y may be absent and, if present, is selected from the
group consisting of a carboxylic acid, carboxamide,
protected carboxamide, an amino resin, and a hydroxy
resin; or

a pharmaceutically acceptable salt of one or more of the
25 quinazolinones in the mixture.

2. The library of claim 1, wherein R³ is methyl.

3. The library of claim 2, wherein R¹ is selected from the group consisting of the α -carbon and side chain of an amino acid as provided in Table I, n-prop-1,3-yl, n-prop-1,1-yl, n-pent-1,5-yl, n-hex-1,6-yl, p-benzyl, 2-chloro-p-phenyl, p-phenyl, 2-methyl-m-phenyl, 2-hydroxy-p-phenyl, and 2-(phenyl)-n-prop-1,3-yl.

4. The library of claim 3, wherein R² is a hydrogen atom.

5. The library of claim 3, wherein R² is halo.


6. The library of claim 5, wherein the halo is selected from the groups consisting of 6,7-difluoro, 6,8-dichloro, and 6,8-dibromo.

7. The library of claim 3, wherein R² is 6,8-dimethyl.

8. The library of claim 3, wherein R² is 6-hydroxyl.

9. The library of claim 3, wherein R² is a 1,4-butadienyl moiety such that a naphthyl ring results.

10. A library of quinazolinone derivatives comprising a mixture of five or more quinazolinone derivatives of the structure:



wherein:

- 5 R¹ is selected from the group consisting of a hydrogen atom, C₁ to C₆ alkyl; C₁ to C₆ substituted alkyl, C₇ to C₁₂ phenylalkyl, C₇ to C₁₂ substituted phenylalkyl, phenyl, substituted phenyl, C₃ to C₇ cycloalkyl, and C₃ to C₇ substituted cycloalkyl;
- 10 R² is selected from the group consisting of a hydrogen atom, halo, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₂ to C₇ alkenyl, C₂ to C₇ alkynyl, C₁ to C₆ substituted alkyl, C₂ to C₇ substituted alkenyl, C₂ to C₇ substituted alkynyl, C₁ to C₄ alkoxy, C₁ to C₄ acyloxy, C₁ to C₄ acyl, C₃ to C₇ cycloalkyl, C₃ to C₇ substituted cycloalkyl, C₃ to C₇ cycloalkenyl, C₃ to C₇ substituted cycloalkenyl, a heterocyclic ring, C₇ to C₁₂ phenylalkyl, C₇ to C₁₂ substituted phenylalkyl, phenyl, substituted phenyl, cyclic C₂ to C₁₀ alkylene,

substituted cyclic C₂ to C₁₀ alkylene, cyclic C₂ to C₁₀
heteroalkylene, substituted cyclic C₂ to C₁₀
heteroalkylene, carboxy, protected carboxy,
hydroxymethyl, protected hydroxymethyl,
5 (monosubstituted)amino, protected
(monosubstituted)amino, (disubstituted)amino,
carboxamide, protected carboxamide, C₁ to C₄ alkylthio,
C₁ to C₄ alkylsulfonyl, methylsulfonylamino, C₁ to C₄
alkylsulfoxide, phenylthio, substituted phenylthio,
10 phenylsulfoxide, substituted phenylsulfoxide,
phenylsulfonyl, and substituted phenylsulfonyl

R⁴ is selected from the group consisting of C₁ to C₆
alkyl; C₁ to C₆ substituted alkyl, C₇ to C₁₂
phenylalkyl, C₇ to C₁₂ substituted phenylalkyl, phenyl,
15 substituted phenyl, naphthyl, substituted naphthyl,
and a heterocyclic ring;


Y may be absent and, if present, is selected from the
group consisting of carboxylic acid, carboxamide,
protected carboxamide, an amino resin, and a hydroxy
20 resin; or

a pharmaceutically acceptable salt of one or more of the
quinazolinone derivatives in the mixture.

11. The library of claim 10, wherein

- R¹ is selected from the group consisting of the α -carbon and side chain of an amino acid as provided in Table I, *m*-prop-1,3-yl, *n*-prop-1,1-yl, *N*-pent-1,5-yl, *m*-hex-1,6-yl, *p*-benzyl, 2-chloro-*p*-phenyl, *p*-phenyl, 2-methyl-*m*-phenyl, 2-hydroxy-*p*-phenyl, and 2-(phenyl)-*n*-prop-1,3-yl;
- R² is selected from the group consisting of a hydrogen atom, 6,7-difluoro, 6,8-dichloro, 6,8-dibromo, 6,8-dimethyl, 6-hydroxy, and a 1,4-butadienyl moiety such that a naphthyl ring results;
- R⁴ is selected from the groups consisting of phenyl, 2,4-dichlorophenyl, 2-naphthyl, 2,5-dimethylphenyl, 3,4-difluorophenyl, 4-bromophenyl, 3-(4-methylphenoxy)phenyl, 4-methoxyphenyl, biphenyl, 6-methyl-pyridin-2-yl, 2-(methoxy)-naphthyl, 2,4,5-trimethoxyphenyl, and 4-(dimethylamino)phenyl; and
- Y may be absent and, if present, is selected from the group consisting of carboxylic acid, carboxamide, protected carboxamide, an amino resin, and a hydroxy resin.

12. A library of 1,2-dihydro quinazolinone derivatives comprising a mixture of five or more quinazolinone derivatives of the structure:




wherein:

- 5 R¹ is selected from the group consisting of a hydrogen atom, C₁ to C₆ alkyl; C₁ to C₆ substituted alkyl, C₇ to C₁₂ phenylalkyl, C₇ to C₁₂ substituted phenylalkyl, phenyl, substituted phenyl, C₃ to C₇ cycloalkyl, and C₃ to C₇ substituted cycloalkyl;
- 10 R² is selected from the group consisting of a hydrogen atom, halo, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₂ to C₇ alkenyl, C₂ to C₇ alkynyl, C₁ to C₆ substituted alkyl, C₂ to C₇ substituted alkenyl, C₂ to C₇ substituted alkynyl, C₁ to C₄ alkoxy, C₁ to C₄ acyloxy, C₁ to C₄ acyl, C₃ to C₇ cycloalkyl, C₃ to C₇ substituted cycloalkyl, C₃ to C₇ cycloalkenyl, C₃ to C₇ substituted cycloalkenyl, a heterocyclic ring, C₃ to
- 15

- C₁₂ phenylalkyl, C₇ to C₁₂ substituted phenylalkyl, phenyl, substituted phenyl, cyclic C₂ to C₁₀ alkylene, substituted cyclic C₂ to C₁₀ alkylene, cyclic C₂ to C₁₀ heteroalkylene, substituted cyclic C₂ to C₁₀ heteroalkylene, carboxy, protected carboxy, hydroxymethyl, protected hydroxymethyl, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, C₁ to C₄ alkylthio, C₁ to C₄ alkylsulfonyl, methylsulfonylamino, C₁ to C₄ alkylsulfoxide, phenylthio, substituted phenylthio, phenylsulfoxide, substituted phenylsulfoxide, phenylsulfonyl, and substituted phenylsulfonyl
- 5
- 10
- R³ is selected from the group consisting of C₁ to C₆ alkyl, C₂ to C₇ alkenyl, C₂ to C₇ alkynyl, C₁ to C₆ substituted alkyl, C₂ to C₇ substituted alkenyl, C₂ to C₇ substituted alkynyl, C₃ to C₇ cycloalkyl, C₃ to C₇ substituted cycloalkyl, C₇ to C₁₂ phenylalkyl, C₇ to C₁₂ substituted phenylalkyl, phenyl, and substituted phenyl;
- 15
- 20
- Y may be absent and, if present, is selected from the group consisting of a carboxylic acid, carboxamide, protected carboxamide, an amino resin, and a hydroxy resin; or
- 25
- a pharmaceutically acceptable salt of one or more of the quinazolinone derivatives in the mixture.

13. A library of quinazolinone derivatives comprising a mixture of five or more quinazolinone derivatives of the structure:



wherein:

R¹ is selected from the group consisting of a hydrogen atom, C₁ to C₆ alkyl; C₁ to C₆ substituted alkyl, C₇ to C₁₂ phenylalkyl, C₇ to C₁₂ substituted phenylalkyl, phenyl, substituted phenyl, C₃ to C₇ cycloalkyl, and C₃ to C₇ substituted cycloalkyl;

10

R² is selected from the group consisting of a hydrogen atom, halo, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₂ to C₇ alkenyl, C₂ to C₇ alkynyl, C₁ to C₆ substituted alkyl, C₂ to C₇ substituted alkenyl, C₂ to C₇ substituted alkynyl, C₁ to C₄ alkoxy, C₁ to C₇

15


acyloxy, C₁ to C₆, acyl, C₂ to C₆, cycloalkyl, C₃ to C₆,
substituted cycloalkyl, C₃ to C₆, cycloalkenyl, C₃ to C₆,
substituted cycloalkenyl, a heterocyclic ring, C₃ to
C₁₂, phenylalkyl, C₇ to C₁₂, substituted phenylalkyl,
5 phenyl, substituted phenyl, cyclic C₂ to C₁₀, alkylene,
substituted cyclic C₂ to C₁₀, alkylene, cyclic C₂ to C₁₀
heteroalkylene, substituted cyclic C₂ to C₁₀
heteroalkylene, carboxy, protected carboxy,
hydroxymethyl, protected hydroxymethyl,
10 (monosubstituted)amino, protected
(monosubstituted)amino, (disubstituted)amino,
carboxamide, protected carboxamide, C₁ to C₄, alkylthio,
C₁ to C₄, alkylsulfonyl, methylsulfonylamino, C₁ to C₄
alkylsulfoxide, phenylthio, substituted phenylthio,
15 phenylsulfoxide, substituted phenylsulfoxide,
phenylsulfonyl, and substituted phenylsulfonyl

R³ is selected from the group consisting of C₁ to C₆,
alkyl, C₂ to C₆, alkenyl, C₂ to C₆, alkynyl, C₁ to C₆,
substituted alkyl, C₂ to C₆, substituted alkenyl, C₂ to
20 C₆, substituted alkynyl, C₃ to C₆, cycloalkyl, C₃ to C₆,
substituted cycloalkyl, C₃ to C₁₂, phenylalkyl, C₇ to C₁₂,
substituted phenylalkyl, phenyl, and substituted
phenyl;

R⁵ is selected from the group consisting of C₁ to C₆,
25 alkyl; C₁ to C₆, substituted alkyl, C₁ to C₄, alkoxy, C₁
to C₁₂, phenylalkyl, C₇ to C₁₂, substituted phenylalkyl,
phenyl, and substituted phenyl.

- Y may be absent and, if present, is selected from the group consisting of a carboxylic acid, carboxamide, protected carboxamide, an amino resin, and a hydroxy resin; or
- 5 a pharmaceutically acceptable salt of one or more of the quinazolinones in the mixture.

14. A library of quinazolinone derivatives comprising a mixture of five or more quinazolinone derivatives of the structure:



10 wherein:

R^1 is selected from the group consisting of a hydrogen atom, C_1 to C_6 alkyl; C_1 to C_6 substituted alkyl, C_7 to C_{12} phenylalkyl, C_7 to C_{12} substituted phenylalkyl,

phenyl, substituted phenyl, C₃ to C₇ cycloalkyl, and C₃ to C₇ substituted cycloalkyl;

R² is selected from the group consisting of a hydrogen atom, halo, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₂ to C₇ alkenyl, C₂ to C₇ alkynyl, C₁ to C₆ substituted alkyl, C₂ to C₇ substituted alkenyl, C₂ to C₇ substituted alkynyl, C₁ to C₄ alkoxy, C₁ to C₇ acyloxy, C₁ to C₇ acyl, C₃ to C₇ cycloalkyl, C₃ to C₇ substituted cycloalkyl, C₃ to C₇ cycloalkenyl, C₃ to C₇ substituted cycloalkenyl, a heterocyclic ring, C₇ to C₁₂ phenylalkyl, C₇ to C₁₂ substituted phenylalkyl, phenyl, substituted phenyl, cyclic C₂ to C₁₀ alkylene, substituted cyclic C₂ to C₁₀ alkylene, cyclic C₂ to C₁₀ heteroalkylene, substituted cyclic C₂ to C₁₀ heteroalkylene, carboxy, protected carboxy, hydroxymethyl, protected hydroxymethyl, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, C₁ to C₄ alkylthio, C₁ to C₄ alkylsulfonyl, methylsulfonylamino, C₁ to C₄ alkylsulfoxide, phenylthio, substituted phenylthio, phenylsulfoxide, substituted phenylsulfoxide, phenylsulfonyl, and substituted phenylsulfonyl


R⁶ is selected from the group consisting of a hydrogen atom, C₁ to C₆ alkyl; C₁ to C₆ substituted alkyl, C₇ to C₁₂ phenylalkyl, C₇ to C₁₂ substituted phenylalkyl, phenyl, substituted phenyl, C₃ to C₇ cycloalkyl, C₃ to

C, substituted cycloalkyl, carboxylic acid, carboxamide, and protected carboxamide;

Y may be absent and, if present, is selected from the group consisting of a carboxylic acid, carboxamide, protected carboxamide, an amino resin, and a hydroxy resin; or

a pharmaceutically acceptable salt of one or more of the quinazolinone derivatives in the mixture.

10 15. A library of quinazolinone derivatives comprising a mixture of five or more quinazolinone derivatives of the structure:



wherein:

15 R¹ is selected from the group consisting of a hydrogen atom, C₁ to C₆ alkyl; C₁ to C₆ substituted alkyl, C₁ to C₁₂ phenylalkyl, C₁ to C₁₂ substituted phenylalkyl, phenyl, substituted phenyl, C₃ to C₇ cycloalkyl, and C₃ to C₇ substituted cycloalkyl;

20 R² is selected from the group consisting of a hydrogen atom, halo, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₂ to C₇ alkenyl, C₂ to C₇ alkynyl, C₁ to C₆ substituted alkyl, C₂ to C₇ substituted alkenyl, C₂ to C₇ substituted alkynyl, C₁ to C₄ alkoxy, C₁ to C₇

acyloxy, C₁ to C₇, acyl, C₃ to C₇, cycloalkyl, C₃ to C₇,
substituted cycloalkyl, C₃ to C₇, cycloalkenyl, C₃ to C₇,
substituted cycloalkenyl, a heterocyclic ring, C₇ to
C₁₂, phenylalkyl, C₇ to C₁₂, substituted phenylalkyl,
5 phenyl, substituted phenyl, cyclic C₂ to C₁₀, alkylene,
substituted cyclic C₂ to C₁₀, alkylene, cyclic C₂ to C₁₀
heteroalkylene, substituted cyclic C₂ to C₁₀
heteroalkylene, carboxy, protected carboxy,
hydroxymethyl, protected hydroxymethyl,
10 (monosubstituted)amino, protected
(monosubstituted)amino, (disubstituted)amino,
carboxamide, protected carboxamide, C₁ to C₄, alkylthio,
C₁ to C₄, alkylsulfonyl, methylsulfonylamino, C₁ to C₄
alkylsulfoxide, phenylthio, substituted phenylthio,
15 phenylsulfoxide, substituted phenylsulfoxide,
phenylsulfonyl, and substituted phenylsulfonyl;

R³ is selected from the group consisting of C₁ to C₆,
alkyl, C₂ to C₇, alkenyl, C₂ to C₇, alkynyl, C₁ to C₆,
substituted alkyl, C₂ to C₇, substituted alkenyl, C₂ to
20 C₇, substituted alkynyl, C₃ to C₇, cycloalkyl, C₃ to C₇,
substituted cycloalkyl, C₃ to C₁₂, phenylalkyl, C₇ to C₁₂,
substituted phenylalkyl, phenyl, and substituted
phenyl;

Y may be absent and, if present, is selected from the
25 group consisting of a carboxylic acid, carboxamide,
protected carboxamide, an amino resin, and a hydroxy
resin;

Z is a heteroaromatic ring having from two to six carbons and one or two heteroatoms selected from the group consisting of nitrogen, sulfur and oxygen; or

a pharmaceutically acceptable salt of one or more of the
5 quinazolinones in the mixture.

16. The library of claim 15, wherein Z is selected from the group consisting of pyridino ring and pyrazino ring.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/00886

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D239/88 C07D475/02 C07D471/04 A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,92 13535 (DWIVEDI) 20 August 1992 see claims ---	1,2
X	FR,M,1 678 (MERCK) 4 February 1963 see page 1 - page 6 ---	1,2
X	FR,A,2 248 048 (ROUSSEL-UCLAF) 16 May 1975 see page 1 - page 8 ---	1,2
X	FR,A,2 187 353 (INOUE) 18 January 1974 see page 1 - page 15 ---	1,2
X	FR,A,2 092 090 (CASSELLA) 21 January 1972 see page 1 - page 10 ---	1,2
X	GB,A,1 187 348 (CHINOIN) 8 April 1970 see claims; example 10 ---	1,2
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *A* document member of the same patent family

Date of the actual completion of the international search

24 January 1997

Date of mailing of the international search report

06.02.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Francois, J

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/00886

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR,M,3 806 (HOECHST) 3 January 1966 see page 1 - page 3 ---	1
X	FR,M,2 846 (MERCK) 12 October 1964 see page 1 - page 4 ---	1,10
X	GB,A,982 207 (ORGAMOL) 3 February 1965 see page 1 - page 4 ---	1,2
X	FR,M,4 601 (BOEHRINGER) 21 November 1966 see page 1 - page 5 ---	1,2
X	US,A,3 558 610 (H.BREUER ET AL.) 26 January 1971 see the whole document ---	1,2,10
X	FR,A,2 078 650 (PFIZER) 5 November 1971 see the whole document ---	1,2
X	US,A,2 786 055 (H.VERNON ET AL.) 19 March 1957 see column 1 - column 5 ---	1,2
X	ARZNEIMITTEL FORSCHUNG DRUG RESEARCH., vol. 43, no. 1(6), 1993, AULENDORF DE, pages 663-667, XP002023719 A.RAGHU RAM RAO: "NEW ESTERS OF HETERYL ACETIC AND MERCAPTOACETIC ACIDS." see page 663 - page 666 ---	1,2
X	JOURNAL OF MEDICINAL CHEMISTRY, vol. 34, 1991, WASHINGTON US, pages 1492-1503, XP002023720 M.MALAMAS ET AL.: "QUINAZOLINACETIC ACIDS AND RELATED ANAL. AS ALDOSE REDUCTASE INHIBITORS." see page 1492 - page 1503 ---	1,2
X	CHEMICAL ABSTRACTS, vol. 111, no. 10, 1989 Columbus, Ohio, US; abstract no. 130542z, Y.A. MOHAMED: "SYNTHESIS AND SCREENING OF NEWER 6,8-DICHLORO-2-ME.-3(S)-4(3H)QUINZOLINONES AS ANTIMICROBIAL AGENTS." page 419; column 1; XP002023721 see abstract ---	1,2
X	& PROC. INDIAN NATL SCI. ACAD., PART A, vol. 55, no. 1, 1989, INDIA, pages 87-95, ---	1,2
	-/--	

INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/US 96/00886

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 96, no. 34, 1982 Columbus, Ohio, US; abstract no. 143306x, EL-KHAWAGA: "SYNTHESIS OF PEPTIDES CONTAINING A QUINAZOLIN-4-ONE MOIETY" page 807; XP002023722 see abstract	1,2
X	& GAZZ. CHIM. ITAL., vol. 111, no. 9-10, 1981, ITAL., pages 441-442,	1,2
X	--- CHEMICAL ABSTRACTS, vol. 92, no. 7, 1980 Columbus, Ohio, US; abstract no. 58720a, V.ZOTTA: "STUDIES OF THE 4-QUINAZOLONE SERIES.PART III." page 670; XP002023723 see abstract	1,2
X	& FARMACIA, vol. 27, no. 2, 1979, BUCHAREST, pages 65-68,	1,2
X	--- CHEMICAL ABSTRACTS, vol. 82, no. 28, 1975 Columbus, Ohio, US; abstract no. 140060n, V.MISRA: "SEARCH FOR POTENTIAL ANTICONSULSANTS. III." page 623; XP002023724 see abstract	1,2
X	& INDIAN J. PHARM., vol. 36, no. 6, 1974, INDIA, pages 142-144,	1,2
X	--- CHEMICAL ABSTRACTS, vol. 80, no. 3, 1974 Columbus, Ohio, US; abstract no. 14888j, L.AVRAM: "2-STYRYL-4-(3H)QUINAZOLINONE DERIVATIVES.1." page 428; XP002023725 see abstract	1,10
X	& FARMACIA, vol. 21, no. 6, 1973, BUCHAREST, pages 365-372, -----	1,10

1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/00886

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
Claims searched completely: 3-9
Claims searched incompletely: 1, 2, 10-16
see next page
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 96/00886

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9213535	20-08-92	NONE	
FR-M-1678		NONE	
FR-A-2248048	16-05-75	GB-A- 1466571	09-03-77
		BE-A- 821327	22-04-75
		CA-A- 1024515	17-01-78
		CH-A- 593948	30-12-77
		DE-A- 2450429	30-04-75
		JP-A- 50077381	24-06-75
		LU-A- 71155	24-06-75
		NL-A- 7413894	25-04-75
		US-A- 3928354	23-12-75
		US-A- 3991193	09-11-76
FR-A-2187353	18-01-74	JP-C- 1010894	29-08-80
		JP-A- 49014482	07-02-74
		JP-B- 54042991	17-12-79
		AR-A- 197148	15-03-74
		AT-B- 330187	25-06-76
		AU-B- 474505	22-07-76
		AU-A- 5671773	12-12-74
		BE-A- 800595	01-10-73
		CA-A- 998339	12-10-76
		CH-A- 582160	30-11-76
		DE-A- 2329815	03-01-74
		GB-A- 1443829	28-07-76
		NL-A- 7308045	14-12-73
FR-A-2092090	21-01-72	AT-A- 306027	15-02-73
		AT-A- 306028	15-02-73
		AT-A- 306029	15-02-73
		BE-A- 766242	25-10-71
		CA-A- 932332	21-08-73
		CH-A- 556343	29-11-74
		CH-A- 553790	13-09-74
		CH-A- 553788	13-09-74
		DE-A- 2020234	18-11-71
		GB-A- 1312391	04-04-73
		NL-A- 7105069	27-10-71

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/00886

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A-2092090		US-A- 3748327	24-07-73
GB-A-1187348	08-04-70	BE-A- 716174	04-11-68
		CA-A- 925869	08-05-73
		CH-A- 526539	15-08-72
		DE-A- 1670497	27-01-72
		FR-M- 7892	04-05-70
		NL-A, B 6807919	09-12-68
		SE-B- 335128	17-05-71
		US-A- 3673188	27-06-72
FR-M-3806		BE-A- 648093	19-11-64
		CH-A- 447181	
		CH-A- 447182	
		CH-A- 447183	
		DE-B- 1231705	
		DE-B- 1249281	
		FR-A- 1404524	10-11-65
		GB-A- 1053063	
		NL-A- 6405448	19-11-64
		SE-B- 314074	01-09-69
		SE-B- 314075	01-09-69
		SE-B- 314076	01-09-69
		US-A- 3322756	30-05-67
FR-M-2846		NONE	
GB-A-982207		CH-A- 419143	
		NL-A- 286960	
FR-M-4601		CH-A- 457450	
		CH-A- 487901	31-03-70
		CH-A- 492720	30-06-70
		DE-B- 1229094	
		FR-A- 1426488	14-04-66
		GB-A- 1055843	
		US-A- 3418319	24-12-68
US-A-3558610	26-01-71	DE-A- 1670416	11-02-71

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/00886

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A-2078650	05-11-71	BE-A- 762996 DE-A- 2106946 GB-A- 1313218 US-A- 3696102	16-08-71 16-09-71 11-04-73 03-10-72
US-A-2786055	19-03-57	NONE	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.